Clinical Trial

Adhesion and Safety of Rotigexole Compared to Neupro®

Study acronym: START
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 7, 2025 (before its estimated October 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg/24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the innovator product, Neupro® 8 mg/ 24 hours transdermal patch, manufactured by UCB Pharma S.A., Belgium, after 24 hours of application
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-07.
Trial Details
NCT Number NCT07015346
Lead Sponsor Eva Pharma
Collaborators: MARC-CRO
Conditions Idiopathic Parkinson Disease
Enrollment 40 participants
Start Date 2025-09-01
Primary Completion 2025-10-15 (estimated)
Study Completion 2025-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-07